Shares of Theratechnologies Inc. (TSE:TH - Get Free Report) hit a new 52-week high during trading on Tuesday . The company traded as high as C$3.13 and last traded at C$3.08, with a volume of 88466 shares trading hands. The stock had previously closed at C$2.91.
Theratechnologies Price Performance
The company has a current ratio of 1.10, a quick ratio of 0.64 and a debt-to-equity ratio of 562.07. The business has a 50-day moving average of C$2.07 and a 200 day moving average of C$1.91. The firm has a market capitalization of C$137.48 million, a PE ratio of -16.61, a price-to-earnings-growth ratio of -8.50 and a beta of 1.73.
Theratechnologies (TSE:TH - Get Free Report) last posted its quarterly earnings data on Thursday, October 10th. The company reported C$0.09 EPS for the quarter. Theratechnologies had a negative net margin of 8.47% and a negative return on equity of 1,116.86%. The firm had revenue of C$30.96 million during the quarter. As a group, research analysts anticipate that Theratechnologies Inc. will post 0.0298643 EPS for the current fiscal year.
Theratechnologies Company Profile
(
Get Free Report)
Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.
Featured Articles
Before you consider Theratechnologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theratechnologies wasn't on the list.
While Theratechnologies currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
